COVID-19 Does Not Alter Catatonia Presentation or Treatment Response

The Diagnostic Challenge of Post-Viral Catatonia

The emergence of SARS-CoV-2 has introduced a wide array of acute and long-term neuropsychiatric sequelae, ranging from common mood disorders to severe psychomotor disturbances [1, 2]. Among these, catatonia presents a particularly complex challenge for hospitalists and psychiatrists, often requiring the exclusion of organic etiologies like autoimmune encephalitis (an inflammatory condition where the immune system attacks healthy brain cells) or metabolic derangements [3, 4]. While systemic inflammation and cytokine storms (the massive, uncontrolled release of pro-inflammatory signaling molecules) are known to disrupt cortical-subcortical motor regulation, the specific relationship between viral infection and catatonic symptoms remains poorly defined in clinical guidelines [5, 6]. Clinicians frequently encounter these presentations in intensive care or emergency settings, where differentiating between primary psychiatric illness and virus-induced neuroinflammation is critical for determining the safety of antipsychotic use, which can sometimes exacerbate catatonic symptoms [7, 8]. A new retrospective study now provides longitudinal evidence to clarify whether COVID-19 has fundamentally altered the incidence or nature of this neurobehavioral syndrome.

Pathophysiological Mechanisms and Study Design

Catatonia is a complex neurobehavioral syndrome related to several psychiatric and medical conditions, characterized by a profound disruption in motor and behavioral functioning. The underlying pathophysiological mechanism of catatonia involves dysfunction of cortical-subcortical motor regulation systems, specifically involving the neurotransmitters gamma-aminobutyric acid (GABA), dopamine, and glutamate. These chemical messengers govern the inhibitory and excitatory balance required for fluid movement; their disruption explains the hallmark rigidity and posturing seen in clinical practice. Beyond these neurotransmitter imbalances, researchers have proposed that an increased sympathetic freezing response (an evolutionary survival mechanism where the body becomes immobile under extreme stress) may also serve as a primary driver of the syndrome. This neurobiological framework differs from the typical pathogenesis of neuropsychiatric complications of COVID-19, which are primarily associated with nervous system damage resulting from systemic inflammation and cytokine storm, a massive release of pro-inflammatory signaling molecules that can breach the blood-brain barrier.

To investigate whether the pandemic altered the presentation of this syndrome, three psychiatrists conducted a retrospective chart review over a four-year period at the Erenköy Training and Research Hospital for Mental Health and Neurological Disorders. The study period was divided into two distinct phases: the time before and the time after the first released COVID-19 case in the region on March 11, 2020. The researchers gathered data from the hospital's emergency psychiatry department, outpatient clinics, and inpatient units to ensure a comprehensive clinical sample. The database search utilized specific keywords including catatonia, catatonia-syndrome, and all individual catatonia symptoms listed in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Following the start of the pandemic, the researchers additionally searched for the COVID-19 infection status of each patient to correlate viral history with clinical presentation, providing a direct look at how viral exposure might influence psychiatric acuity.

Comparative Analysis of Pre- and Post-Pandemic Cohorts

The retrospective analysis included a total of 40 patients diagnosed with catatonia, providing a balanced demographic profile for comparison. The cohort consisted of 20 females (50.00%) and 20 males (50.00%), reflecting an equal gender distribution in the clinical sample. To evaluate the impact of the pandemic on the syndrome, the researchers divided the subjects into two distinct groups based on the date of the first local COVID-19 case. This resulted in 18 cases in the pre-COVID-19 group and 22 cases in the post-COVID-19 group, allowing for a longitudinal assessment of how the viral outbreak may have influenced the incidence and presentation of catatonic symptoms. For the practicing physician, this sample size provides a focused look at the stability of catatonia phenotypes during a period of high environmental and biological stress.

Statistical comparisons between the pre-pandemic and post-pandemic groups revealed a high degree of clinical stability. The researchers found no significant difference between the pre- and post-COVID-19 groups regarding age (p < 0.05) or gender (p < 0.05), suggesting that the demographic profile of patients presenting with catatonia remained consistent despite the societal and biological stressors of the pandemic. Furthermore, there was no significant difference regarding the underlying cause of catatonia (p < 0.05) between the two periods. This indicates that the primary psychiatric or medical etiologies driving the syndrome did not shift toward a predominantly post-viral or inflammatory origin following the emergence of SARS-CoV-2, reinforcing the idea that catatonia remains a final common pathway for diverse pathologies.

Clinical presentation and symptom complexity also remained largely unchanged across the four-year study period. The symptom diversity of catatonia was not statistically significant between the two groups (p < 0.05), implying that the phenotypic expression of the disorder did not become more severe or varied in the wake of the pandemic. While the overall presentation remained stable, the researchers did identify a small subset of patients with recent viral exposure. Specifically, in the post-pandemic period, 2 cases were diagnosed with COVID-19 in the month preceding their catatonia diagnosis. Despite these individual instances of temporal proximity, the aggregate data suggests that the fundamental clinical characteristics and treatment requirements of catatonia have not been altered by the presence of the virus, which may reassure clinicians that existing diagnostic frameworks remain valid.

Clinical Implications for Symptomatic Management

The longitudinal data indicates that the therapeutic approach to catatonia has remained remarkably stable despite the biological stressors introduced by the pandemic. The researchers found no significant difference between the pre-COVID-19 and post-COVID-19 groups regarding the treatment applied (p < 0.05), suggesting that standard protocols, typically involving benzodiazepines or electroconvulsive therapy, remain effective regardless of viral history. This clinical consistency persists even though postinfectious COVID-19 catatonia is identified as a rare neuropsychiatric complication, occurring in only 2 cases within the post-pandemic cohort of 22 patients. While the neuropsychiatric symptomatology in postinfectious COVID-19 is broad, encompassing a wide range of cognitive and behavioral disturbances, the specific motor features of catatonia do not appear to require a deviation from established management pathways.

These findings also clarify the role of inflammatory markers in the development of the syndrome. Although COVID-19 is characterized by systemic cytokine activity, evidence of acute phase activation in catatonia has been shown rarely in previous medical literature. Acute phase activation refers to the rapid change in plasma protein concentrations, such as C-reactive protein, in response to inflammation. The results of this study further support the unclear role of acute phase reactants in catatonia pathogenesis, as the clinical presentation did not shift toward an inflammatory phenotype following the emergence of the virus. Because the understanding of pathogenesis remains fairly limited, particularly concerning how viral triggers interact with cortical-subcortical circuits, the researchers conclude that symptomatic management is recommended as an appropriate strategy. For the practicing clinician, this means that while COVID-19 can precede catatonic states, the syndrome should be treated according to standard clinical guidelines rather than as a distinct inflammatory sub-type, ensuring that patients receive validated interventions without delay.

References

1. Rogers J, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. 2020. doi:10.1016/s2215-0366(20)30203-0

2. Efstathiou V, Stefanou M, Demetriou M, et al. New‑onset neuropsychiatric sequelae and ‘long‑COVID’ syndrome (Review). Experimental and Therapeutic Medicine. 2022. doi:10.3892/etm.2022.11641

3. Mulder J, Feresiadou A, Fällmar D, et al. Autoimmune Encephalitis Presenting With Malignant Catatonia in a 40-Year-Old Male Patient With COVID-19. American Journal of Psychiatry. 2021. doi:10.1176/appi.ajp.2020.20081236

4. Smith CM, Komisar J, Niu KL. Case 26-2020: A Woman with Altered Mental Status and Left-Sided Weakness. New England Journal of Medicine. 2021. doi:10.1056/nejmc2030849

5. Rogers J, Oldham M, Fricchione GL, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology. 2023. doi:10.1177/02698811231158232

6. Kalin NH. COVID-19 and Stress-Related Disorders. American Journal of Psychiatry. 2021. doi:10.1176/appi.ajp.2021.21040371

7. Carmassi C, Pacciardi B, Gravina D, et al. Pharmacological Treatment of Acute Psychiatric Symptoms in COVID-19 Patients: A Systematic Review and a Case Series. International Journal of Environmental Research and Public Health. 2022. doi:10.3390/ijerph19094978

8. Trajkovski T, Marić N. Use of anxiolytics and hypnotic drugs during COVID-19 pandemic: The literature review. Medicinski Podmladak. 2022. doi:10.5937/mp73-35916